Across TCGA pan-cancer cohorts, ECI2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ECI2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ECI2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ECI2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, ACC, and HNSC are the cancer types where ECI2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.185	0.586	.008	15	view →
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
HNSC	DFS	Median	IV	0.128	0.669	.011	6	view →
LUAD	OS	Median	All	0.572	0.813	.033	5	view →
UCEC	DFS	Median	All	1.000	0.831	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ECI2 tumor-vs-normal RNA expression · all ECI2 data types